NCT02118961View on ClinicalTrials.gov

Study of BK1301 (DTaP Vaccine) as a Booster in Adolescents

PHASE3CompletedINTERVENTIONAL
Enrollment

446

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
DiphtheriaTetanusPertussis
Interventions
BIOLOGICAL

Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP vaccine, BK1301)

0.5 mL, subcutaneous injection

BIOLOGICAL

Adsorbed Diphtheria-Tetanus Combined Toxoid (DT toxoid)

0.1 mL, subcutaneous injection

Trial Locations (7)

Unknown

Investigational site, Fukuoka

Investigational site, Itoshima-shi

Investigational site, Kasuga-shi

Investigational site, Hiroshima

Inverstigational site, Kumagaya-shi

Investigational site, Shizuoka

Inverstigational site, Shinjuku-ku

Sponsors
All Listed Sponsors
collaborator

The Research Foundation for Microbial Diseases of Osaka University

OTHER

lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY